Sign In
×Brief
Company Status: | Listed |
Business Activity: | Manufacture of pharmaceuticals and medicine. |
Current Capital: | 200.00 Million Riyal |
Current No. of Shares (M) (M): |
IPO Facts
Issue Type: | IPO |
Status: | Listed |
Exchange Market: | TASI |
Sector: | Health care |
Country: | Saudi Arabia |
Offered Shares (M): | |
Offered Percentage: | 30.00 % |
Offer Price (Riyal): | 82.00 |
Issue Volume (M Riyal): | 492.00 |
Premium: | 72.00 Riyal |
Available Shares (Individual): | |
Minimum Subscription (Individuals): | |
Maximum Subscription (Individuals): | 0.60 Million Shares |
Available Shares (Institutions): | 5.40 Million Shares |
Minimum Subscription (Institutions): | 10.00 Thousand Shares |
Maximum Subscription (Institutions): | 0.99 Million Shares |
Eligibility : | _ Participating Parties, _ Individual Investors . |
Use of Proceeds: | The net Offering Proceeds will be distributed, after deducting the Offering Expenses estimated at (SAR 30 million), to the Selling Shareholders according to the number of shares owned by each selling shareholder of the offered shares, The Company will not receive any part of the Offering Proceeds . |
Restrictions on Dealing in Shares: | The Existing Substantial Shareholders who own 5% or more of the Company’s shares may not dispose of any Shares during a period of 6 months from the date on which trading of the Offer Shares commences on the Main Market "Lock-up Period", After the said share restriction period has elapsed, the Substantial Shareholders have the right to dispose of their shares without the need to obtain prior consent from the Authority. |
Prospectus: | Downloads |
: | - |
Key Dates
Capital Market Authority Approval: | 12/6/2023 |
The minimum & maximum offering price: | 1/30/2024 |
Subscription End Date: | 2/1/2024 |
Allocation Date: | 2/8/2024 |
Distribution Date: | 2/14/2024 |
Listing Date: | 2/27/2024 |
Major Shareholders
Name | No. of Shares | Holding | Value |
---|---|---|---|
Tabbaa National Holding Company | 8.44 | 42.18 % | 1,219.85 |
Talal Youssef Mahmoud Zahid | 2.94 | 14.70 % | 425.12 |
Advisors
Lead Manager: | Alinma Investment Company |
Underwriter: | Alinma Investment Company |
Financial Advisor: | Aldukheil Financial Group |
Legal Advisor: | Mohammed AlDhabaan And Partners |
Auditor: | KPMG Consulting Co. |
Receiving Bank: | Alinma Bank, The Saudi National Bank |
IPO results
Proceeds: | SAR 2670.22 million |
Subscription Percentage: | 4527% |
No. of Subscribers: | 807.46 thousand subscribers |
Allocation: | 2 shares per individual subscriber & The remaining shares will be allocated on a pro rata basis at around 0.095% on average . |
Chart - Middle East Pharmaceutical Industries Co.
Share Performance
Last Price: | 144.60 |
Change: | 1.55 % |
Market Cap (M): | 2,888.00 |
Turnover: | 14,312,471.00 |
Transactions: | 1,934.00 |
Share Stats
First Day Open: | 90.20 |
First Day High: | 106.60 |
First Day Low: | 90.20 |
First Day Close: | 106.60 |
1st Day Change: | 30.00 % |
1st Month Change: | 101.46 % |
1st year Change: | - |
Since listing: | 76.10 % |
Related News
Avalon Pharma debuts today as 2nd listing on TASI in 2024Argaam Special27/02/2024
Avalon Pharma to debut on Tadawul on Feb. 27Argaam25/02/2024
Retail subscription to 600,000 Avalon Pharma shares on TASI begins todayArgaam Special30/01/2024
Avalon Pharma IPO: Subscription period, key datesArgaam30/01/2024
Here’s a list of receiving banks for Avalon Pharma’s IPOArgaam30/01/2024
Aldukheil Financial Group announces the coverage of Avalon Pharma’s offering for Participating Parties by 138.7 timesArgaam24/01/2024
Avalon Pharma issues prospectus to list 6M shares on TASIArgaam07/01/2024
Call Request